drotrecogin alfa


Also found in: Dictionary, Thesaurus, Wikipedia.

drotrecogin alfa

a thrombolytic agent used to treat severe sepsis associated with organ dysfunction.
References in periodicals archive ?
Use of drotrecogin alfa (activated) in Italian intensive care units: The results of a nationwide survey.
Indeed, while some components of the sepsis bundles require further study, some such as drotrecogin alfa may soon be obsolete given the negative results of a recent landmark study (23).
4% in patients treated with activated drotrecogin alfa compared with 24.
Drotrecogin alfa (activated) is a novel biotechnology product and represents a new class of drug for a very complex disease state, for which there is no approved treatment," said John Lechleiter, Ph.
Drotrecogin alfa (Xigris) is indicated only for adult patients with severe sepsis who are at high risk of death.
While drotrecogin alfa (DA) has been employed in patients with Methicillin-resistant Staphylococcus aureus (MRSA) severe sepsis and septic shock, its utility in TSS remains unclear.
SEATTLE -- When it comes to initiating therapy with drotrecogin alfa in patients with severe sepsis, the earlier the better.
Drotrecogin alfa, a biologic agent used to treat adults with severe sepsis who are at high risk of death, may not be appropriate for patients with single organ dysfunction and recent surgery, and should be administered only after careful consideration of the potential risks and benefits, according to a new warning by Eli Lilly & Co.
Some panelists cited a need for more data to confirm the study already completed by Eli Lilly, which found that treatment with drotrecogin alfa (activated) was associated with lower mortality in patients with severe sepsis.
Drotrecogin alfa (recombinant human activated protein C) in severe sepsis-a New Zealand viewpoint.
The researchers drew the patient population from placebo groups in the Integrated Database of Severe Sepsis and Xigris Therapy, a repository of data from trials for Lilly's drotrecogin alfa activated (Xigris).
We aimed to estimate the potential number of patients eligible for treatment with drotrecogin alfa (activated) when applying different international criteria.